Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.47 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.45 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25581067 | 1.00 | CRBN (0.55) | CRBNDDB1CSNK1A1IKZF2SALL4 | |
| SCHEMBL26251333 | 0.83 | CRBN (0.66) | CRBNDDB1CSNK1A1IKZF2 | |
| SCHEMBL31158929 | 0.83 | CRBN (0.56) | CRBNDDB1CSNK1A1IKZF2GSPT1 | |
| SCHEMBL29521599 | 0.83 | CRBN (0.58) | CRBNDDB1CSNK1A1IKZF2GSPT1 | |
| SCHEMBL31305140 | 0.83 | CRBN (0.58) | CRBNDDB1CSNK1A1IKZF2GSPT1 | |
| SCHEMBL24572309 | 0.82 | IKZF2 (0.57) | CRBNDDB1IKZF2 | |
| SCHEMBL31159006 | 0.82 | CRBN (0.54) | CRBNDDB1CSNK1A1IKZF2GSPT1 | |
| SCHEMBL20046704 | 0.81 | CRBN (0.56) | CRBNDDB1CSNK1A1IKZF2 | |
| SCHEMBL29547522 | 0.81 | CRBN (0.56) | CRBNDDB1CSNK1A1IKZF2 | |
| SCHEMBL31736599 | 0.81 | CRBN (0.56) | CRBNDDB1CSNK1A1IKZF2SALL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | CRBN 9/4885DDB1 445/4885CSNK1A1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.